Search
Filter Results
- Resource Type
- Book2
- Book Print2
- Article1
- Result From
- Lane Catalog1
- PubMed1
- SearchWorks (biomedical subset) 1
-
Year
- Journal Title
- Proc Eur Dial Transplant Assoc1
Search Results
Sort by
- BookUwe M. Martens, editor.Contents:
Erlotinib
Lapatinib
Regorafenib
Crizotinib
Cabozantinib: multi-kinase inhibitor of MET, AXL, RET, and VEGFR2
Vemurafenib
Trametinib (GSK1120212)-- Everolimus
Vismodegib
Larotrectinib (LOXO-101)
Palbociclib, the first of a new class of cell cycle inhibitors
Cobimetinib (GDC-0973, XL518)
Lenvatinib: a tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET
Afatinib
Olaparib
Gefitinib
Alectinib
Osimertinib .Digital Access Springer 2018Access via Recent results in cancer research ; 2018; 211LocationVersionCall NumberItems - ArticleSandberg L, Blohmé I, Brynger H, Lindholm A, Gelin LE.Proc Eur Dial Transplant Assoc. 1977;14:277-84.The importance of HLA matching was studied for 319 primary cadaveric kidney transplantations during the period 1969-1976. During 1969-1972 the HLA match was the basis for recipient selection and most cases belonged to match grade 0 or 1. Graft survival was significantly better for match grade 0. Within match grade 1 cases with one foreign HLA B antigen had lower graft survival than cases with one foreign HLA A antigen, indicating the importance of the HLA B series. During 1973-1976 the HLA match was hardly considered in recipient selection. HLA matching during this period seemed to be of less importance, except for match grade 0 and the totally mismatched cases. When matching was performed for the HLA B series, it was found that graft survival was significantly improved when no or only one foreign HLA B antigen was present. The prognosis for cases with foreign HLA B antigen was significantly better during the later period.